Outstanding presentation by Durga S. Borkar, MD, MMCi at FLORetina 2024! She shared key findings from our Phase 2 study on FAS inhibition with intravitreal ONL1204 for macula-off rhegmatogenous retinal detachment. Thank you for your commitment to helping patients see the future. #Floretina #RetinaInnovation #Neuroprotection #ONL1204 #RetinalDetachment
ONL Therapeutics
Biotechnology Research
Ann Arbor, Michigan 3,095 followers
Helping patients see the future
About us
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.
- Website
-
http://www.onltherapeutics.com
External link for ONL Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Ann Arbor, Michigan
- Type
- Privately Held
- Founded
- 2011
- Specialties
- Ophthalmic Drug Development, Glaucoma, Geographic Atrophy, and Retinal Detachment
Locations
-
Primary
Get directions
524 S Main St
Suite 110
Ann Arbor, Michigan 48104, US
Employees at ONL Therapeutics
-
Marian Nakada, Ph.D.
Using BIG for GOOD. Making strategic investments for Johnson & Johnson Innovation - JJDC
-
Connie Chang
Chief Operating Officer at ONL Therapeutics
-
Linda Kemnitz
Executive Administrator at ONL Therapeutics
-
Sushanta Mallick, PhD, MBA
Chief Development Officer, ONL Therapeutics
Updates
-
Thank you Lejla Vajzovic, MD, FASRS for your presentation on our Phase 1b study on Fas inhibition with ONL1204 for Geographic Atrophy at FLORetina 2024! Together, we're lighting the way to new AMD discoveries! #Floretina #RetinaInnovation #Neuroprotection #ONL1204 #DryAMD #GeographicAtrophy
-
-
Yesterday, our CEO David Esposito presented on “Targeting Fas Pathway: ONL’s Approach to Geographic Atrophy” during FLORetina 2024’s New Horizons in Retinal Diagnosis & Treatments session. We're lighting the way to new AMD discoveries. Thanks for your leadership, David! #RetinaInnovation #Neuroprotection #ONL1204 #DryAMD #GeographicAtrophy
-
-
FLORetina 2024 is underway! Visit us at booth 28 to learn about our Galaxy Clinical Trial - a Phase 2 study exploring ONL1204 for Dry AMD/GA, featuring a novel treatment approach using Fas inhibition. And don't miss our CEO David Esposito's presentation during the New Horizons in Retinal Diagnosis & Treatments session on Saturday, Dec. 7, from 11:30 am – 12:30 pm CET in the San Giovanni Room. We're lighting the way to new AMD discoveries! Fun fact: The #Floretina meeting is being held at the Fortezza da Basso (fortress) in Florence, Italy, constructed between 1534 and 1537. #RetinaInnovation #Neuroprotection #ONL1204 #DryAMD
-
-
We're excited to see you at FLORetina 2024 in just one week! Drop by booth 28 to learn about our upcoming Galaxy Clinical Trial – a Phase 2 study of ONL1204 in patients with Dry AMD/GA, featuring our novel treatment approach using Fas inhibition. In addition, our Co-founder and Chief Scientific Officer David Zacks will share insights on ONL1204 during the meeting: • New Horizons in Retinal Diagnosis & Treatments • Targeting Fas Pathway: ONL Therapeutics’ Approach to Geographic Atrophy • Saturday, Dec. 7, 2024 • 11:30 am – 12:30 pm (local time) • San Giovanni Room We're lighting the way to new AMD discoveries! #Floretina #RetinaInnovation #Neuroprotection #ONL1204 #DryAMD
-
-
Proud to have our COO Connie Chang present at the Retina Innovation Showcase during the Ophthalmology Innovation Summit. Her presentation highlighted ONL’s pioneering Fas inhibition platform technology and our Dry AMD/GA Phase 1b study data, setting the stage for our upcoming Phase 2 Galaxy Study. Thank you for your leadership and dedication, Connie! #OIS #OISXIV #RetinaInnovation #Neuroprotection #ONL1204 #DryAMD Ophthalmology Innovation Source
-
-
Team ONL is lighting the way to new AMD discoveries at the Ophthalmology Innovation Summit hosted by the Ophthalmology Innovation Source. Proud of our mission-driven team working to protect and improve vision of patients with retinal diseases. #OIS #OISXIV #RetinaInnovation #Neuroprotection #ONL1204
-
-
Great session at the Morning Startup Bootcamp to kick-start the Ophthalmology Innovation Summit, hosted by Ophthalmology Innovation Source. Our CEO David Esposito participated in a panel discussion on funding platform technologies alongside leaders from Repoxegen Therapeutics, Oculis and ExSight Ventures. Thank you, David, for sharing your expertise and leadership in advancing innovation. #OIS #OISXIV #RetinaInnovation
-
-
Proud to see our COO Connie Chang paying it forward—guiding and inspiring the next generation of life science innovators!
On Wednesday we had our third MBVF lecture with guest speaker Connie Chang from ONL Therapeutics. She gave a great talk on the "Power of Choice: Integrating Big Pharma, Small Biotech, and Academic Research," clarifying the skills and perspectives needed in different size organizations and how to navigate career changes. Thank you to Michigan Biomedical Venture Fund for once again partnering with Nucleate to provide the food. The last lecture of this series will be on December 4th, with more information to come. Interested in venture capital and gaining hands on experience? The deadline to apply for the Nucleate Michigan x MBVF Venture Capital fellowship is today! As a Fellow, you’ll: - Generate technology landscaping reports in a defined target area - Explore a subsection of innovation at the University of Michigan - Work alongside MBVF experts in due diligence, gaining key venture capital insights 🔗 Apply to the Nucleate X MBVF Venture Fellowship here: https://lnkd.in/gMSdwYFn
-
-
-
-
-
+1
-
-
Our team is headed to San Diego this week for the Ophthalmology Innovation Summit hosted by the Ophthalmology Innovation Source. We’re looking forward to connecting with industry leaders, exploring advancements and clinical learnings, and sharing our own insights through two featured sessions: David Esposito, CEO (Panelist) Morning Startup Bootcamp Case Study 2: Funding Challenges for “Platform Technologies” Friday, Nov. 22 | 10:40 am PT Connie Chang, COO (Presenter) Retina Innovation Showcase Saturday, Nov. 23 | 11:15 am PT If you’re attending, we’d love to connect and discuss the latest in retinal disease research and treatment. #OIS #OISXIV #RetinaInnovation #Neuroprotection #ONL1204
-